)

Guardant Health (GH) investor relations material
Guardant Health Investor Day 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Strategic vision and innovation
Mission centers on transforming cancer care through non-invasive blood-based diagnostics, expanding into multi-disease detection using the Smart Platform and Infinity AI Learning Engine.
Smart Platform and InfinityAl drive innovation, integrating genomics, epigenomics, and multimodal data for oncology, screening, and multi-disease applications.
Over 1 million patient samples have been collected, creating a unique data moat that accelerates AI-driven discovery and product development across 500+ diseases.
Shield, the blood-based CRC screening test, is expanding to multi-cancer detection, leveraging real-world data, AI, and large-scale data collection initiatives.
Strategic collaborations, such as with Quest Diagnostics and Pfizer, expand access and accelerate clinical utility studies.
Business and financial performance
2025 revenue guidance is $915–$925 million, reflecting 24–25% year-over-year growth, with oncology, biopharma, and screening all contributing.
2028 revenue target increased to $2.2 billion (34% CAGR), driven by volume growth, ASP expansion, and new product launches.
Gross margin target for 2028 is 65–70%, supported by COGS reductions, automation, and AI-driven efficiencies.
Free cash flow breakeven is now expected in Q4 2027, a year ahead of previous guidance.
Oncology and screening ASPs projected to rise, with Reveal targeting $1,000 and Guardant360 Liquid $3,300 by 2028.
Product and market leadership
Guardant360 Liquid and Tissue lead the therapy selection market, with rapid adoption of Smart Platform-powered applications and FDA PMA submission for Guardant360 Liquid.
Reveal is the leading tissue-free MRD test, with new Reveal Ultra product offering 1 ppm sensitivity and broad validation across therapies.
Shield is the first FDA-approved blood test for CRC screening, now included in NCCN guidelines and expanding to multi-cancer detection.
Biopharma business is growing at double-digit rates, with over 190 partners and expanding companion diagnostics pipeline.
Oncology business benefits from new smart applications, therapy monitoring, and international expansion.
Next Guardant Health earnings date

Next Guardant Health earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage